CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2008-11-04): Pioglitazone improves fatty liver disease in nondiabetics

Clinical

Pioglitazone improves fatty liver disease in nondiabetics

Last Updated: 2008-11-04 17:43:25 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Treatment with pioglitazone leads to a number of beneficial changes in nondiabetics with nonalcoholic steatohepatitis (NASH), UK researchers report in the October issue of Gastroenterology.

Dr. Guruprasad P. Aithal of University Hospitals NHS Trust, Nottingham, and colleagues note that a recent study showed a reduction in hepatic fat and inflammation in diabetic NASH patients treated with the agent, and they sought to determine whether this might also be true in those without diabetes.

For their study, they randomized 74 such patients to standard diet and exercise and 30 mg per day of pioglitazone or placebo.

At 1 year, active treatment patients showed a mean weight gain of 2.77 kg compared to a loss of 0.55 kg in the placebo group. They also showed a significant drop in glucose, A1C, insulin C peptide, and alanine aminotransferase levels.

There were also beneficial changes in other markers and, in those evaluated, a significant reduction in hepatocellular injury and in fibrosis.

In light of these findings, the researchers conclude, "Larger extended trials are justified to assess the long-term efficacy of pioglitazone in this patient group."

Gastroenterology 2008;135:1176-1184.

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.